| abstract |
The present disclosure relates to therapeutic management and diagnostic methods for esophageal cancer based on the expression levels of biomarker miRNAs. Aspects of the disclosure relate to a method of treating esophageal cancer (EC) in a patient, the method comprising: when the patient is determined to have an expression level of one or more miRNAs in a sample from the patient, the one or more miRNAs are expressed in a sample from the patient. When the expression level of one or more miRNAs increases or decreases, the patient is diagnosed with esophageal cancer, and the one or more miRNAs are selected from: mir-15b, miR-17, mir-18a, mir-21, mir- 23a, mir-24-2, mir-25, mir-27a, mir-93, mir-103, mir-106b, mir-129-2, mir-139, mir-146b, mir-148a, mir-151, miR-155, mir-181a-1, mir-181a, mir-181b-1, mir-181b, mir-182, mir-183, mir-192, mir-194-1, mir-194-2, mir- 196a‑1, mir‑196a‑2, mir‑196b, mir‑205, mir‑215, mir‑223, mir‑224, mir‑335, mir‑338, mir‑375, mir‑421, mir‑484, mir-505, mir-769, mir-944, mir-1468, mir-3648, and let-7i; and administering an effective amount of esophageal therapy to the diagnosed patient. |